The proportion of wild type DDR genes was 54.7% in all EOC patients; 30.4% in serous carcinoma, 66.7% in endometrioid carcinoma and 73.4% in clear cell carcinoma. This evidence concerns the gene DDR1 and clear cell adenocarcinoma.